A druggable chromatin vulnerability in suppressive neutrophils restores antitumor immunity
Yang, F.; Bao, Y.; Qiao, Y.; Cruz, G.; Young, E.; Mannan, R.; Zhang, Y.; Goodrich, M.; Cao, Y.; Luo, J.; Paturu, R.; Mahapatra, S.; Tien, J. C.-Y.; Xu, R.; Kobayashi, M.; Liu, Y.; Coleski, A.; Su, F.; Cao, X.; Miner, S. J.; Vatan, L.; Sudharshan, R.; Rao, A.; Samajdar, S.; Abbineni, C.; Ramachandra, M.; Piel, J. C.; Hentemann, M.; Kryczek, I.; Zou, W.; Xiao, L.; Chinnaiyan, A. M.
Show abstract
Many cancers evade immunity by converting neutrophils into polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), but the chromatin mechanisms that maintain this pathological state remain unclear. Here we show that tumor-induced suppressive neutrophils depend on mSWI/SNF chromatin remodeling. Two orally bioavailable mSWI/SNF ATPase antagonists, a degrader and a catalytic inhibitor, produced immune-dependent tumor control across syngeneic models, including tumors resistant to PD-1 blockade, and enhanced checkpoint therapy without overt toxicity. Treatment rapidly depleted intratumoral PMN-MDSCs, restored functional CD8+ T cells, and blocked tumor explant-induced expansion and suppressive activity of mouse and human PMN-MDSCs. mSWI/SNF antagonism collapsed chromatin accessibility and PU.1/C/EBP{beta} occupancy at regulatory elements that sustain PMN-MDSC identity. Thus, suppressive neutrophils harbor a druggable chromatin vulnerability that can be exploited to restore cancer immunity.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- In vivo CRISPR screens reveal Serpinb9 and Adam2 as regulators of immune therapy response in lung cancer 95%
- Combinatorial immunotherapies overcome MYC-driven immune evasion 95%
- Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors 95%
Similar papers in this journal
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 94%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 94%
- Cell lineage as a predictor of immune response in neuroblastoma 94%
Similar papers in this journal
- Tumor-Initiating Cells Fine-tune the Plasticity of Neutrophils to Sculpt a Protective Niche 97%
- An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers 95%
- Systematic Elucidation and Pharmacological Targeting of Tumor-Infiltrating Regulatory T Cell Master Regulators 95%
Similar papers in this journal
- ETS1 Orchestrates a Hybrid EMT Program Driving in vivo Metastasis and Immune Evasion 95%
- IL-6 underlies microenvironment immunosuppression and resistance to therapy in glioblastoma 95%
- CIP2A interacts with TopBP1 and is selectively essential for DNA damage-induced basal-like breast cancer tumorigenesis 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.